Introduction
The 14-3-3 proteins are a highly conserved family of proteins that have important roles in a wide range of cell signalling, cell cycle and survival pathways (reviewed in Aitken, 1996; Baldin, 2000) . The 14-3-3 proteins bind to speci®c phosphoserine containing motifs (Muslin et al., 1996) , and their dimeric nature allows them to act as intra-and intermolecular bridges (Liu et al., 1995; Xiao et al., 1995) , eectively colocalizing proteins in a phosphorylation-dependent manner.
The involvement of 14-3-3 proteins in cell cycle regulation was initially described in ®ssion yeast where the 14-3-3 homologue rad24 is required for the G2 phase cell cycle checkpoint arrest following DNA damage (Ford et al., 1994) . The mechanism by which rad24 interacts with this checkpoint was in part de®ned with the discovery that the cdc25 phosphatase, a promotor of G2/M progression, directly bound rad24 and loss of this binding corresponded to the loss of replication and DNA damage checkpoint responses (Zeng and Piwnica-Worms, 1999) . Rad24 binds other components of the checkpoint pathway including chk1, which may to be involved in the maintenance of the G2 checkpoint arrest (Chen et al., 1999; Raleigh and O'Connell, 2000) .
The regulation of G2/M progression in humans is more complex than in yeast, although the basic mechanisms are conserved. In yeast, a single cdc25 phosphatase is primarily responsible for dephosphorylation of the inhibitory tyrosine 15 residue on cdc2 and resultant activation of cyclin B/cdc2, the protein kinase complex responsible for progression into mitosis. In humans, three cdc25 isoforms have been identi®ed, and two of these, cdc25B and cdc25C phosphatases, have roles in regulating G2/M progression (Millar et al., 1991; Gabrielli et al., 1996; Lammer et al., 1998) . Multiple alternatively spliced forms of cdc25B are expressed, although only the two variants, cdc25B2 and cdc25B3, are expressed as detectable levels of protein (Baldin et al., 1997b; Forrest et al., 1999) . Cdc25B protein expression is tightly regulated, accumulating rapidly as cells enter G2 phase and then destroyed as cells exit mitosis (Gabrielli et al., 1996; Forrest et al., 1999) . The proteosome-dependent destruction of cdc25B is triggered by cyclin A/cdc2-dependent phosphorylation in mitosis (Baldin et al., 1997a) . Cdc25C is expressed at a constant level throughout the cell cycle. In vivo, cdc25B is active during G2 phase, before cdc25C is activated at the G2/M transition (Gabrielli et al., 1997a,b; Lammer et al., 1998) , and cdc25B appears to be more ecient than cdc25C at promoting mitosis (Karlsson et al., 1999) . This correlates with the in vitro activity of cdc25B and cdc25C, with the unmodi®ed form of cdc25B able to eciently activate the cyclin B1/cdc2 kinase complex, whereas only the hyperphosphorylated form of cdc25C eciently catalysed this activation (Gabrielli et al., 1997a) . The role of cdc25B in G2/M progression has not yet been fully de®ned, although the timing of its activation in G2 phase and cytoplasmic localization at prophase suggest that it may initiate the activation of cyclin B/cdc2, possibly in the cytoplasm at prophase (Nishijima et al., 1997; De Souza et al., 2000) . It may also be responsible for the activation of cyclin A/cdk2 in early G2 phase (Goldstone et al., 2001) .
In G2 phase checkpoint arrested human cells, the cdc25-dependent activation of the G2 phase pool of cyclin A/cdk2, and cyclin B/cdc2 are blocked (Herzinger et al., 1995; Jin et al., 1996; Gabrielli et al., 1997b) . The role for 14-3-3 in the G2 checkpoint mechanism as de®ned in ®ssion yeast appears to be conserved in higher eukaryotes, and 14-3-3-dependent regulation of cdc25C function has been implicated in this checkpoint arrest (Peng et al., 1997; Yu et al., 1998) . Cdc25C has been shown to bind 14-3-3, and loss of 14-3-3 binding results in an abrogation of the G2 checkpoint arrest in response to ionizing radiation (Peng et al., 1997) . 14-3-3 has also been implicated in the p53-dependent G2 checkpoint arrest, with 14-3-3s identi®ed as a p53 regulated gene, and over-expression of 14-3-3s producing a G2 arrest (Hermeking et al., 1997) , possibly through binding with the G2/M regulators wee1 and cyclin B1/cdc2 (Chan et al., 1999) .
The mechanism by which 14-3-3 binding regulates cdc25C function is not clear. In yeast, cdc25 relocates from the nucleus to the cytoplasm in G2 arrested cells, eectively separating cdc25 from its substrate cyclin B/ cdc2, and the loss of the cytoplasmic relocation has been correlated with the loss of 14-3-3 binding (LopezGirona et al., 1999; Zeng and Piwnica-Worms, 1999) . Mutation of the single 14-3-3 binding site in cdc25C, S216, also results in reduced cytoplasmic localization of the mutant protein (Dalal et al., 1999) . However, in G2 arrested mammalian cells cyclin B1/cdc2 is cytoplasmically retained, thus 14-3-3 dependent cytoplasmic localization of cdc25C would not provide an obvious advantage for maintaining the G2 arrest (O 'Connell et al., 2000) .
The regulation of the second mitotic cdc25 isoform, cdc25B, in the G2 checkpoint arrest, and the consequences of loss of regulation of this mitotic regulator to cell cycle progression and cellular integrity have so far been largely overlooked. In G2 phase checkpoint arrested cells, the normal G2 phase accumulation of cdc25B protein occurs, although the phosphatase is low activity form (Gabrielli et al., 1997b) . The regulation of cdc25B is not well understood although phosphorylation has a role in its activation and destruction (Baldin et al., 1997a; Gabrielli et al., 1997a) . Cdc25B has also been demonstrated to bind 14-3-3 proteins (Conklin et al., 1995; Mils et al., 2000) , and mutation of the major 14-3-3 binding site in cdc25B, S323, results in the complete loss of its cytoplasmic localization (Davezac et al., 2000) . In this study we have examined the contribution of 14-3-3 binding to S323 to the regulation of cdc25B activity in G2 checkpoint arrested cells. We demonstrate that point mutation of S323 or removal of the N-terminal regulatory domain are activating mutations, and that mutation of the S323 abrogates 14-3-3 binding to this site and increases access of the substrate cyclin/cdks to the catalytic site of cdc25B, thereby removing an inhibitory restriction on cdc25B activity.
Results
Cdc25B has two 14-3-3 binding sites Using bacterially expressed GST fusion constructs of full-length cdc25B2 and cdc25B3 splice variants, N and C-terminal truncations of both splice variants, and S323 point mutants (Figure 1) , we have con®rmed S323 as the major 14-3-3 binding site on cdc25B. GSHagarose puri®ed GST-cdc25B2, or S323 to Ala mutant (S323A), was incubated in HeLa cell lysate either without or with Mg 2+ /ATP, washed and 14-3-3 binding analysed by immunoblotting the eluted GST-cdc25B2 for 14-3-3. The wild type protein bound 14-3-3 strongly, but the S323A mutant had diminished binding ( Figure 2a ). The residual binding was due to the existence of a second 14-3-3 site in the N-terminal regulatory domain of cdc25B, as mutation of S323 in the C-terminal catalytic domain reduced the 14-3-3 binding to almost undetectable levels, while the Nterminal domain displayed comparatively weak Mg 2+ / ATP-dependent binding of 14-3-3 (Figure 2b,c) . Phosphorylation of the S323 site provided the optimal 14-3-3 binding site, but it was not absolutely required. Low level of 14-3-3 binding was detected to both the wild type and S323A mutant forms of the GST-Cterminal protein incubated with HeLa cell lysate in the presence, but not absence of Mg Cdc25B binds 14-3-3 in vivo A similar pattern of 14-3-3 binding was detected in vivo when full-length cdc25B splice variants, S323A and S323 to Glu (S323E; to mimic phosphorylation of S323) mutants, and N-terminal constructs were transiently expressed in HeLa cells. Immunoprecipitation of cdc25B using a speci®c antibody to the Nterminal domain of cdc25B revealed 14-3-3 associated with the wild type forms of both cdc25B2 and cdc25B3 and the truncated N-terminal domain, but only barely detectable levels of 14-3-3 were associated with the S323 mutant proteins (Figure 3a) . The weak binding of 14-3-3 to the S323A mutant appeared to be speci®c, and 14-3-3 bound to both wild type and S323A mutant proteins was removed with the zwitterionic detergent Empigen (Figure 3b ), which eciently dissociated 14-3-3 from Raf-1 (Thorson et al., 1998) .
Over-expression of cdc25B overcomes the G2 checkpoint arrest
We and others have demonstrated that cdc25B has an essential function in G2/M progression (Gabrielli et al., 1996 (Gabrielli et al., , 1997a Lammer et al., 1998) , and its function appears to be blocked in G2 phase checkpoint arrested cells (Gabrielli et al., 1997b) . Therefore, the functional consequences of dysregulating cdc25B by over-expressing either cdc25B wild type, S323 mutants, or the Cterminal catalytic domain of cdc25B (expressed as a chimera with Green Fluorescent Protein, GFP-Cterminal), in HeLa cells arrested at the G2 phase checkpoint with etoposide were assessed. Strong overexpression of either the wild type, S323 mutants, or the GFP-C-terminal overcame the G2 phase arrest, with cdc25B over-expressing cells accumulating in G1 phase by 10 h after transfection to a similar or greater extent than that observed at 10 h after addition of 5 mM caeine to overcome the G2 arrest (Figure 4a ,b). All the cdc25B constructs promoted progression through the G2 arrest to a similar extent therefore only the cdc25B2 wild type version is shown.
When transfected cells were analysed by¯uores-cence microscopy, a high proportion of abnormal and catastrophic mitoses were observed at 10 h after transfection in the cdc25B over-expressing cells compared to either untransfected controls or catalytically inactive CR/SK mutant over-expressing cells. The phenotypes ranged from relatively mild eects where apparently normal microtubule spindles formed but the condensed chromosomes fail to congress to the metaphase plate (abnormal), through to cells with hypercondensed chromatin and malformed microtubule structures (catastrophe; Figure 5a ). The con- (a), and the immunoprecipitates were washed either with (+) or without (7) the zwitterionic detergent Empigen to dissociate 14-3-3 from cdc25B. The level of cdc25B2 S323A is higher than the wild type to aid in the detection of the associated 14-3-3 sequences of these abnormal and catastrophic mitoses is initially cells with multiple nuclei, although in the longer term this lead to cell death as few cdc25B overexpressing cells were detected by 24 h after transfection. Quantitative dierences between wild type and mutant cdc25B over-expression were observed in terms of their eects on mitosis. Although the proportions of abnormal and catastrophic mitoses varied from experiment to experiment, overexpression of the inactive mutant consistently produced the lowest proportion of these abnormal phenotypes. Overexpression of the active versions of cdc25B resulted in increased levels of the various aberrant mitotic phenotypes, with the wild type proteins producing the fewest catastrophes and the GFP-C-terminal the highest proportion, in some experiments 450% of the GFP-C-terminal expressing cells having a catastrophe phenotype (Figure 5b ).
Mutation of S323 and removal of the N-terminal domain activate cdc25B
In a previous study we demonstrated that removal of the N-terminal regulatory domain increased the catalytic activity of recombinant cdc25B in vitro (Gabrielli et al., 1997a) . The dierences observed between the cdc25B wild type and GFP-C-terminal constructs in producing mitotic catastrophes also appeared to be related to the relative catalytic activities of these constructs in vivo, measured by the activation of endogenous cyclin B1/cdc2. When equivalent levels of cdc25B2 wild type and GFP-C-terminal were expressed in etoposide blocked HeLa cells, the GFP-C-terminal construct catalysed strong activation of cyclin B1/cdc2 within 6 h, whereas cdc25B2 wild type Figure 4a were immuno¯uores-cently stained for cdc25B over-expression, DNA and microtubules (MT). The abnormal mitosis shown was with cdc25B2 wild type over-expression, and the catastrophe was with GFP-C-terminal over-expression. (b) Quantitation of the normal, abnormal and mitotic catastrophe phenotypes from transfections of the indicated cdc25B (both cdc25B2 and cdc25B3 splice variants) into G2 arrested cells. In each case 100 ± 200 transfectants were counted, those with strong cdc25B staining and normal nuclear and microtubule morphologies being scored as normal. The data are mean and standard deviation from 4 ± 6 independent experiments 14-3-3 regulates cdc25Brequired 8 h to produce a similar level of activation (Figure 6a,b) .
The dierence in the activities of wild and S323 mutant forms of cdc25B was not due to an increase in the intrinsic activity of the S323 mutant protein, as bacterially expressed GST-fusions of wild type and mutant cdc25B displayed identical activity in vitro (data not shown). However, when the activity of the over-expressed wild type and S323 mutant proteins were assessed in G2 phase arrested HeLa cells by measuring the level of endogenous cyclin B1/cdc2 activation, only low levels of S323 mutant overexpression was required to maximally activate cyclin B1/cdc2 whereas a similar degree of cyclin B1/cdc2 activation was only seen with very high level wild type cdc25B over-expression (Figure 7a ). Only the S323A mutant data is shown, but both the Ala and Glu mutant forms displayed similar activities. The low activity of the wild type protein suggested that mutation of S323 to a non-phosphorylatable residue relieved inhibition due to loss of 14-3-3 binding at this site rather than dephosphorylation of S323, as the S323E mutation which also failed to support 14-3-3 binding had similar activity to the S323A mutant.
These data suggested that 14-3-3 binding to S323 blocked cdc25B activity. This was further demonstrated by co-expressing cdc25B with a myc-tagged version of 14-3-3b. When cdc25B wild type or S323A mutant were co-expressed with myc-tagged 14-3-3b, activation of endogenous cyclin B1/cdc2 was inhibited in cells co-expressing wild type cdc25B and 14-3-3b, but co-expression of 14-3-3b had only a small eect on the activity of the S323A mutant (Figure 7b,c) . The cdc25-dependent activation of the G2 phase pool of cyclin A/cdk2 is also blocked in G2 phase arrested HeLa cells (Gabrielli et al., 1997b) , and the activation of this complex was also assayed in these experiments, with the results mirroring those for the activation of cyclin B1/cdc2 (Figure 7c ). The over-expression of 14-3-3b appears not to have any direct eect on cyclin B1/cdc2 activity or activation as over-expression of 14-3-3b did not eect G2/M transition (Hermeking et al., 1997) . Thus, the ability of co-expressed 14-3-3b to block the cdc25-dependent activation of both cyclin A/cdk2 and cyclin B1/cdc2 must be related to the 14-3-3 binding of the wild type cdc25B, which is defective in the S323 mutant.
Mutation of S323 increases substrate cyclin/cdks access to the catalytic site
Mutation of the catalytic Cys to Ser produces a substrate trapping mutant of cdc25B, tightly binding the cyclin/cdk substrates (Xu and Burke, 1996; Gabrielli et al., 1997a) , and the double mutant of the catalytic Cys and Arg to Ser and Lys respectively (CR/ SK), produced a substrate trap with greatly increased anity for the cyclin/cdk substrates (unpublished observations). We have used substrate trapping mutants of S323 wild type and S323A mutant proteins to examine the mechanism by which the S323A mutation increased cdc25B activity in vivo. Using conditions that immunodepleted 490% of cdc25B, immunoprecipitates of the over-expressed cdc25B were immunoblotted for the presence of the bound cyclins and cdks. When the substrate trapping versions of S323 wild type and S323A mutant proteins were expressed in etoposide treated, G2 arrested cells, cyclin A and cyclin B1, cdc2 and cdk2 were detected in the CR/SK mutant but not wild type cdc25B immunoprecipitates (Figure 8 ). High level expression of the S323 wild type protein was required to achieve binding of detectable levels of the substrate cyclin/cdk complexes, which were still lower than the levels detected with low level expression of the S323 mutant protein (Figure 8 ). (a) G2 arrested HeLa cells were transfected with increasing amounts of plasmid (2 ± 20 mg DNA) for either cdc25B2 wild type (wt) or S323A mutant, or empty vector (vec) and harvested after 6 h. Lysates were blotted for the expression of cdc25B (the weak band in the vector control lane is endogenous cdc25B) and assayed for cyclin B1 immunoprecipitate kinase activity (H1K). (b) G2 arrested HeLa cells were transfected with either empty vector (vec), cdc25B2 wild type (wt) or S323A mutant, with or without myc-tagged 14-3-3b. Lysates were immunoblotted for over-expression of cdc25B and 14-3-3, the latter detected using an anti-myc tag antibody. (c) The same lysates as in (b) were assayed for cdk2 and cyclin B1 immunoprecipitate kinase activity High level expression of the S323 mutant was not associated with signi®cantly more cyclin/cdks. This result re¯ected the cyclin B1/cdc2 activation data, where only high level expression of wild type cdc25B activated the cyclin B1/cdc2, whereas low level expression of the S323A mutant achieved similar or greater activation (Figure 7a ). These observation demonstrated that abrogating 14-3-3 binding to S323 activated cdc25B by increasing the access of the substrates to the active site.
Discussion
The inhibition of cdc25 activity during S and G2 phase, and in the G2 checkpoint arrest, contributes to the maintenance of the premitotic state. In human cells, two cdc25 isoforms have essential roles in G2/M progression, cdc25B and cdc25C. The control of cdc25C activity in the G2 checkpoint arrest has been the focus of intense study since the discovery that phosphorylation of S216 site is potentially regulated by the checkpoint kinases chk1 and chk2/cds1 (Peng et al., 1997; Sanchez et al., 1997; Matsuoka et al., 1998; Blasina et al., 1999) . Here we have demonstrated that regulating cdc25B activity is also important to ensure normal entry and progression through mitosis, and that 14-3-3 binding to the S323 site contributes to this regulation. Mutation of the S323 site is an activating mutation, and in this is similar to the activating mutation of S216 in cdc25C, which increases the ability of the mutant cdc25C to bypass DNA damage induced G2 arrest (Peng et al., 1997) .
We have con®rmed an earlier report that S323 is a major 14-3-3 binding site on cdc25B (Mils et al., 2000) , although contrary to that report we ®nd that 14-3-3 binding is strongly favoured by phosphorylation of S323. A low level of 14-3-3 binding to both the wild type S323 and S323A mutant motif was observed in the presence of Mg 2+ , suggesting that the phosphorylation of the site acts to either increase the anity or decrease the o rate of 14-3-3. The absolute requirement for phosphoserine in the 14-3-3 binding site has been established primarily using peptide analogues of the 14-3-3 binding sites, which possibly do not account for weaker interaction due to either more distal sequence determinants or possible secondary or tertiary structural features not mimicked by the peptides (Muslin et al., 1996; Yae et al., 1997) . These other contributing factors may also explain the apparent 14-3-3 isoform speci®c binding reported with full-length proteins which is not found with the peptide analogues.
One of the functional consequences of 14-3-3 binding to cdc25B would appear to be changes is its cellular localization, with mutation of the S323 site resulting in a loss of cytoplasmic localization of this protein (Davezac et al., 2000) . In this report we have demonstrated that disruption of 14-3-3 binding to the S323 site increases the catalytic activity of cdc25B towards two G2 phase substrates, cyclin A/cdk2 and cyclin B1/cdc2. This eect appears to be independent of cellular localization as relative substrate binding of the S323 wild type and S323A substrate trapping mutants, which were both predominantly nuclear proteins (unpublished observations), re¯ected the activity of their respective catalytically active versions of cdc25B. In ®ssion yeast, mutation of the consensus 14-3-3 binding sites on cdc25 resulted in attenuation of the G2 checkpoint arrest (Zeng and Piwnica-Worms, 1999) . The authors of this study ascribed the loss of regulation to the inability of the mutant protein to relocate to the cytoplasm during the checkpoint arrest, which in the wild type yeast eectively separates cdc25 from its substrate cyclin/cdk (Lopez-Girona et al., 1999) . A recent study has demonstrated that nuclear localization of cdc25 during the G2 arrest is not sucient to overcome the checkpoint arrest (LopezGirona et al., 2001 ). An earlier study had demonstrated that activation of cdc25 was also blocked in G2 arrested ®ssion yeast (Kovelman and Russell, 1996) , and it may be that 14-3-3 binding regulates cdc25 activity both directly as demonstrated in this report, and indirectly by relocating the cdc25.
The ability of low level over-expression of the S323A mutant cdc25B to activate the mitotic cyclin/cdks and overcome the G2 arrest is evidence that tight regulation of endogenous cdc25B activity is an important component of the G2 phase checkpoint control. The dire consequences of defective regulation are clearly illustrated by the high proportion of abnormal and catastrophic mitotic phenotypes found with S323A and GFP-C-terminal over-expression. The ability of HeLa cells to inhibit the activity of wild type cdc25B when over-expressed to moderately high levels suggests that the availability of 14-3-3 is not a limiting factor, therefore a mechanism similar to the p53-dependent upregulation of 14-3-3s expression is unlikely to have a signi®cant role in blocking cdc25B activity in the G2 checkpoint arrest (Hermeking et al., 1997) . Only when Figure 8 Mutation of the S323 site increases substrate access to the catalytic site of cdc25B. G2 arrested HeLa cells were transfected with either low (5 mg) or high (20 mg) levels of plasmid for wild type (wt), or S323A versions of the substrate trapping CR/SK mutant forms of cdc25B2 and harvested after 6 h. Cdc25B was immunodepleted from the lysates (490% depletion) and the immunoprecipitates immunoblotted for cdc25B, and levels of associated cyclin A, cyclin B1, cdc2 and cdk2 (indicated by the arrowhead) cdc25B was expressed at supra physiological levels was overexpressed 14-3-3 required to down regulate cdc25B activity. Furthermore, 14-3-3s associates with cdc25B only weakly (Mils et al., 2000) , making regulation by this 14-3-3 isoform unlikely. Thus the regulation of 14-3-3 binding to the S323 site is likely to be at the level of phosphorylation. The S216 site on cdc25C, which is identical to the S323 motif in cdc25B, is a substrate for a wide range of kinase in vitro, including c-TAK1 (Peng et al., 1998) , CaM kinase II (Patel et al., 1999) , and the checkpoint kinases chk1 and chk2 (Peng et al., 1997; Blasina et al., 1999) . It is possible that these kinases may also be involved in regulating the conserved S323 site on cdc25B. However, the S323 site did not serve as a major site for chk1 phosphorylation in vitro (Mils et al., 2000) , and in ®ssion yeast, 14-3-3 binding to cdc25 appears to be independent of either chk1 or cds1 function (Chen et al., 1999) .
The mechanism by which 14-3-3 binding to the S323 site on cdc25B restricts access of the substrate cyclin/ cdks to the catalytic site is unclear. The S216 site is the only 14-3-3 consensus binding on cdc25C, and mutation of this residue results in the complete loss of 14-3-3 binding. It appears that cdc25B has at least two functional 14-3-3 binding motifs, the S323 site and a second in the N-terminal domain. Whether the Nterminal site has any functional signi®cance is currently unknown. In vitro, the removal of the N-terminal domain also increases the access of the substrate cyclin/ cdks to the catalytic site (16), and in vivo removal of the N-terminal domain was possibly a stronger activating mutation than S323A. This suggests that 14-3-3 binding to S323 may interact with the Nterminal domain.
14-3-3 binding is a common event in the regulation of both the human mitotic cdc25 activities. Cdc25B activity appears to be directly regulated by 14-3-3 binding to S323, and disruption of this binding increases access of the substrate cyclin/cdks to the catalytic site, thereby activating cdc25B. The kinases which phosphorylate the 14-3-3 binding sites on the cdc25 proteins, and the mechanisms by which the 14-3-3 proteins are removed from the cdc25s are likely to be important players in the checkpoint controls.
Materials and methods

Cdc25B expression constructs and mutation
Mutagenesis of Ser323 to Ala and Glu 14-3-3 binding site mutants were prepared using the U.S.E. mutagenesis kit (Pharmacia). Mutagenic primers 5'-CGG CTC TTC CGC TCT CCG TCC ATG CCC-3' and 5'-CGG CTC TTC AGA TCT CCG GAG ATG CCC TGC-3' were used to convert the 14-3-3 binding motif on cdc25B3 from SPS 323 MP to SPAMP or SPEMP. The primer introduced a BglII restriction enzyme site which facilitated screening of potential clones which were then con®rmed by automated DNA sequencing. The 14-3-3 binding site mutants were produced in pGEXcdc25B3, the resultant plasmid was named pGEXcdc25B3-S323A. The cdc25B2 version was produced by subcloning a fragment containing the cdc25B2 deletion into pGEXcdc25B3-S323A. The C-term GST constructs were produced by digesting pGEXcdc25B3 constructs with BamHI and BsrG1, Klenow ®lling and religation. This removed the N-term yet maintained the reading frame. The cdc25B2 and cdc25B3 N-term GST constructs were produced as described previously (Gabrielli et al., 1996) .
Mammalian expression constructs An eleven amino acid cmyc tag was sublconed into the mammalian expression vector pUCSRa, to yield a vector with a 5' myc tag. pGEM-myc (gift from Professor John Hancock, University of Queensland) was digested with NdeI and HindIII, the fragments were Klenow ®lled and then the smaller fragment containing the insert was gel puri®ed and digested with EcoR1. This digest was then ligated into pUCSRa to produce pUCSRa ± myc. The construct gained a BamH1 site from pGEM-myc which was in the same frame as the BamHI in pGEX2T. The pGEX ± cdc25B2 and cdc25B3 wild type and S323A and S323E mutants were digested with EcoN1, Klenow ®lled and then digested with BamH1. This fragment containing the cdc25B coding region was inserted into the BamHI, SmaI sites of pUCSRa-myc.
GFP-C-terminal was constructed using pRcCMV-GFP (a gift from Dr Norbert Kienzle, Queensland Institute of Medical Research). The BsrG1 ± BamH1 fragment from pUCSRa ± cdc25B3 coding for the C-terminal catalytic domain was subcloned in frame into BsrGI ± BamHI digested pRcCMV-GFP.
pUCSRa-myc 14-3-3 was constructed from pGEX 14-3-3 (gift of Dr Michael Yae, Beth Israel Deaconess Medical Centre, Boston). The 14-3-3 inserts were cut with an enzyme 3' of the 14-3-3 insert (varying depending on the vector and insert) Klenow ®lled, cut with BamHI and subcloned into pUCSRa-myc, cut and ®lled as above.
Cell culture and transfections
HeLa cells were grown in DMEM supplemented with 5% bovine donor serum (Serum Supreme; BioWhittaker). Cells were arrested in G2 phase by addition of 800 nM etoposide 20 ± 24 h prior to transfection. Etoposide was added again 2 h after transfection. 5610 6 G2 phase arrested cells were transfected with up to 20 mg of DNA by electroporation then harvested 6 ± 10 h after transfection. All cells, both attached and¯oating were harvested. Cells were washed with PBS and either ®xed in 70% 7208C ethanol for FACS analysis or stored at 7708C for biochemical analysis. For FACS analysis, the transfected cells were stained for cdc25B overexpression using a cdc25B speci®c antibody and FITC conjugated anti-rabbit secondary antibody, and propidium iodide for DNA content then analysed using a FACSCalibur (Becton Dickson). The cdc25B over-expressing cells were detected due to their increased FITC¯uorescence, or in the case of the GFP-C-terminal high GFP¯uorescence, and the DNA content of the gated cdc25B over-expressing cells determined as reported previously (Gabrielli et al., 1996) .
Immunoprecipitation and immunoblotting
For immunoprecipitation of cdc25B complexes, cells were lysed in 14-3-3 lysis buer (50 mM Tris, 150 mM NaCl, 2 mM EGTA, 2 mM MgSO 4 , 5 mM DTT, 0.1% Tween 20, pH 7.5) supplemented with 5 mg/ml leupeptin, aprotinin, pepstatin A, 0.5 mM PMSF, 10 mM NaF, 0.1 mM sodium orthovanadate for at least 30 min with constant rocking at 48C then centrifuged at full speed in a microfuge for 15 min. The supernatant was incubated overnight at 48C with 0.3 ± 2 mg anti-cdc25B N-terminal antibody with constant mixing, then the antibody bound complexes precipitated with 20 ml of protein A-Sepharose for a further 1 h. The immunoprecipitates were washed three times with lysis buer then eluted with 60 ml of SDS sample buer for analysis by SDS ± PAGE and immunoblotting. Cdc25B immunoprecipitates were probed for the presence of cdc25B using the same antibody as used for the immunoprecipitation, and for the presence of associated 14-3-3 using 14-3-3 pan speci®c antibody (K19, Santa Cruz). In some experiments, the presence of myctagged, over expressed proteins was probed for using antimyc-tag monoclonal antibody (9E10).
Cyclin B1 and cdk2 immunoprecipitate histone H1 kinase assays were preformed as described previously (Gabrielli et al., 1997b) .
In vitro 14-3-3 binding assay Lysate was prepared from asynchronously growing HeLa cells lysed in lysis buer (50 mM Tris pH 7.4, 5 mM EDTA, 250 mM NaCl, 0.1% Triton X100, 2 mM DTT, 5 mM NaF, 0.3 mM sodium orthovanadate and protease inhibitors 5 mg/ ml aprotinin, leupeptin, pepstatin A, 0.5 mM PMSF), cleared by centrifugation, then pre-incubated with GSH-agarose with continuous rocking at 48C for 2 h. The cleared lysate was then incubated with GSH-agarose bound GST ± cdc25B (prepared as described previously (Gabrielli et al., 1997a) . In vitro phosphorylations and 14-3-3 binding was carried out in 400 ml (10 mg/ml protein) of lysate, supplemented with 15 mM MgSO 4 , 2 mM ATP, 5 mM Microcystin, at 308C for 15 min, then an additional 1 mM ATP was added and incubated for a further 15 min. The agarose bound GST fusion proteins were then pelleted and washed three times with NETN (20 mM Tris, 2 mM EDTA, 100 mM NaCl, 0.5% NP-40, pH 8). The GST fusion proteins were eluted at 48C in 10 mM reduced glutathione in phosphatase buer (20 mM Tris pH 8.3, 2 mM EDTA, 5 mM DTT, 150 mM NaCl, 0.1% Triton X100) then analysed by SDS ± PAGE and immunoblotting for the GST fusion proteins and 14-3-3.
Immunofluorescent staining
Etoposide treated, G2 phase arrested HeLa cells were transfected with cdc25B as described above, and plated onto glass coverslips. At 10 h after transfection, the coverslips were washed with PBS then the cells ®xed with 7208C methanol, and stored at 7208C in methanol until required. The cells were rehydrated and immunostained for cdc25B, microtubules and DNA as described previously (Gabrielli et al., 1996) . The proportion of normal, abnormal and catastrophic mitoses were assessed by counting 100 ± 200 mitotic cells per coverslip from 3 ± 6 independent experiments.
